M e d i c i n e A v e 2 1 In renal disease and congestive heart failure/ patients often become refractory to loop diuretic therapy. Increasing the dose can help, yet sometimes even a substantial increase in furosemide can’t give patients the relief they need. ' A beneficial addition—even in patients with diminished renal function. In patients with refractory edema, therapy with ZAROXOLYN' Tablets has been shown ro enhance diuresis even when renal sufficiency is significantly reduced." Chemically distinct from thiazides, ZAROXOLYN"’- Tablets provide: • Synergistic sequential blockade with loop diuretics- • Diuresis in patients with diminished renal function, even with GFRs fcelow 20 miymin' • lifficacy in patients with renal insufficiency who often will not respond to a thiazldeA proven therapy for the treatment of edema. ZAROXOLYN1 Tablets are indicated for the treatment of edema that accompanies renal diseases and CHE Added to furosemide, they can help provide patients with greater diuresis than furosemide alone/' ZAROXOLYN* Tablets may deliver just the “boost" your patients need to overcome resistance to loop diuretic therapy' by: • Blocking sodium reabsorption at the proximal and distal tubules and enhancing the efficiency of loop diuretics’' • Allowing more filtrate to reach the loop of Henle, where furosemide is most effective1 ZAROXOLYN* (metolazone tablets, USPi Tablets are contraindicated in patients with anuria, hepatic coma and precoma, or knowm hypersensitivity to metolazone. Diuretics should not be used concomitantly with lithium. Because of the potential for rapid diuresis, ZAROXOLYN* Tablets should be used with caurion v/hen prescribed concomitantly with loop diuretics (eg, furosemide). If symptoms consistent ’With severe fluid ar.d/or electrolyte imbalance appear (eg, hyponatremia, hypochloremic alkalosis, hypokalemia), ZAROXOLYN* Tablets should be discontinued and supportive measures should be initiated immediately. 'Daily dosage should be based on thorough clinical and laboratory evaluations. ZAROXOLYN Is a registered trademark of Cefcwch Manuacastiz, tr.f. For added results in refractory edema. Tablets ZAKCMOLYN' (metolazone tablets, LISP) IPs not over u n tilyou getpast the a rtifa c ts When female and large-chested or obese male patients undergo myocardial perfusion imaging, there is the potential for images to be peppered with artifacts—possibly resulting in inconclusive studies. Cardiolite’ comes through, especially in these patients. The higher photon energy (140 keV) provides greater anatomical detail to enhance interpretive confidence—which may reduce false-positives and equivocal cases. Cardiolite also offers the unique advantage of direct measurement of both myocardial perfusion and ventricular function from one study. So rather than settle for potentially inconclusive images, use Cardiolite and reduce soft-tissue attenuation. Kit for ihc pfrpjratfoc of Techoeuam Tc99rn Seysmibi Toreduce soft-tissue attenuation Cardiolite comes through [DU PONT) Stress testing should be performed only under the supervision of a qualified physician in a laburato equipped with appropriate resuscitation and support apparatus There have been infrequent reports of sig and symptoms consistent with seizure and severe hypersensitivity after administration 0(Tc99m Sestamili Pleasesrt britfsummaryofprescribing information m adjocoupan*. £■ 1014. OnPont I'harr 208
RkJQdWJsaXNoZXIy NDMwNDAx